---
schema_version: "secwatch.filing_event.v1"
accession: "0001649094-24-000051"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:18:51.110429+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte Q2 net loss $128.7M; cash $1.85B; VAX-31 adult data due Sept 2024

## Summary
- Net loss $128.7M for Q2 2024 vs $68.3M in Q2 2023; R&D expenses $131.5M, up from $72.7M.
- Cash, cash equivalents and investments $1,851.9M as of June 30, 2024, up from $1,242.9M at Dec 31, 2023.
- VAX-31 adult Phase 1/2 topline safety and immunogenicity data expected in September 2024; will then select VAX-24 or VAX-31 for Phase 3.
- VAX-24 infant Phase 2 topline from primary series due by end of Q1 2025; booster data by end of 2025.
- Appointed John Furey to Board; received $9.5M NIAID grant for Chlamydia vaccine program.

## SEC filing metadata
- accession: 0001649094-24-000051
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000164909424000051/0001649094-24-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000164909424000051/pcvx-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001649094-24-000051
- JSON: https://secwatch.observer/filing/0001649094-24-000051.json
- Plain text: https://secwatch.observer/filing/0001649094-24-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.